As per government sources, more than 107,000 people in the U.S. were waiting for an organ transplant in February 2021. Moreover, last year, merely 39,000 such surgeries were performed in the country. Due to such a staggering difference in the number of those who need organ transplants and those who ultimately get it, 17 people die each year in waiting. The reasons are aplenty; despite campaigns and awareness programs by government and international organizations, such as the United Nations (UN) and World Health Organization (WHO), not many are willing to donate their organs.
Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/3d-bioprinting-market/report-sample
Moreover, in certain cases, the organs are not viable, which leads to a further dearth for those in need. This is one of the key reasons that P&S Intelligence says will propel the 3D bioprinting market from $98.6 million in 2015 to $792.5 million by 2022, at a massive 35.9% CAGR between in 2016 and 2022. This is because 3D printing is proving to be a viable solution to creating artificial organs, thus reducing the need for people to donate theirs.
Make an Enquiry before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=3d-bioprinting-market
With years of extensive research and experimentation, 3D-printed organs, such as kidneys, hearts, lungs, pancreas, livers, and intestines, are becoming a reality. Similarly, 3D bioprinting can be used to create tissues or the individual parts of organs, such as heart valves and corneas, along with the skin, blood vessels, and bones. With the increasing incidence of chronic diseases, especially diabetes, cardiovascular diseases (CVDs), cancer, asthma, and chronic obstructive pulmonary disease (COPD), as well as severe cases of infection or injuries, the number of people requiring organ transplants is rising.
Hence, with continuous R&D, the applications of 3D bioprinting will only widen in the years to come.
